Back to top
more

Myriad Genetics: (MYGN)

(Real Time Quote from BATS)

 Add to portfolio

Trades from $3

$21.37 USD

21.37
255,388

-0.73 (-3.30%)

Updated Sep 28, 2016 01:30 PM ET

Volume: 255,388

Open: $22.06

Prior Close: $22.10

5-Strong Sell         5

Value: B | Growth: B | Momentum: D | VGM: A

The Zacks Scorecard is a complimentary set of indicators to use alongside the Zacks Rank. It allows the investor to better focus on the stocks that are the best fit for his or her personal investment style.

We produce five unique ratings, including the Zacks Style Score, which combines the individual style scores into 1 rating:

Zacks Style Score A
Growth Score A
Value Score A
Momentum Score A
Income Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a score of an A or a B in your personal trading style.

Zacks Scorecard Education - Learn more about the Zacks Scorecard

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 25.71%
2 Buy 18.12%
3 Hold 9.91%
4 Sell 5.49%
5 Strong Sell 2.29%
S&P 500 9.79%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The way to access to the Zacks Rank

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Company Summary

Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products. They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease. They have integrated these technologies using bioinformatics and robotics systems to conduct their research efforts on a high-throughput basis. This has enabled them to identify numerous proteins as targets for new drugs and molecular diagnostic tests.

General Information

MYRIAD GENETICS

320 WAKARA WAY

SALT LAKE CITY, UT 84108

Phone: 801-584-3600

Fax: 801-584-3640

Web: http://www.myriad.com

Email: sgleason@myriad.com

Industry MED-BIOMED/GENE
Sector Medical
Fiscal Year End June
Last Reported Quarter 6/30/2016
Next EPS Date 11/1/2016

EPS Information

Current Quarter EPS Consensus Estimate 0.26
Current Year EPS Consensus Estimate 1.06
Estimated Long-Term EPS Growth Rate 13.00
Next EPS Report Date 11/1/2016

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 22.10
52 Week High 46.24
52 Week Low 19.10
Beta 0.56
20 Day Moving Average 1,699,137.63
Target Price Consensus 24.60

MYGN

% Price Change
4 Week 7.59
12 Week -27.78
YTD -50.02
% Price Change Relative to S&P 500
4 Week 8.40
12 Week -30.17
YTD -52.40
Share Information
Shares Outstanding (millions) 69.14
Market Capitalization (millions) 1,527.88
Short Ratio NA
Last Split Date 3/26/2009
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio 0.00
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) 20.81
Trailing 12 Months 13.56
PEG Ratio 1.60
EPS Growth
vs. Previous Year -12.20%
vs. Previous Quarter -12.20%
   
Sales Growth
vs. Previous Year -1.79%
vs. Previous Quarter -2.10%
   
Price Ratios
Price/Book 2.08
Price/Cash Flow 10.64
Price / Sales 2.03
ROE
6/30/16 16.06
3/31/16 16.95
12/31/15 17.49
ROA
6/30/16 14.03
3/31/16 14.88
12/31/15 15.23
Current Ratio
6/30/16 4.35
3/31/16 5.63
12/31/15 5.70
Quick Ratio
6/30/16 3.82
3/31/16 5.25
12/31/15 5.26
Operating Margin
6/30/16 15.85
3/31/16 16.18
12/31/15 16.33
Net Margin
6/30/16 14.98
3/31/16 14.29
12/31/15 13.00
Pre-Tax Margin
6/30/16 22.41
3/31/16 22.08
12/31/15 21.37
Book Value
6/30/16 10.64
3/31/16 10.81
12/31/15 11.05
Inventory Turnover
6/30/16 4.95
3/31/16 5.47
12/31/15 5.15
Debt-to-Equity
6/30/16 0.00
3/31/16 0.00
12/31/15 0.00
Debt to Capital
6/30/16 0.00
3/31/16 0.00
12/31/15 0.00